KalVista Pharmaceuticals Stock Discussion

$KalVista Pharmaceuticals (KALV.US)$  saw significant insider activity this week. On February 3, major shareholder Venrock Healthcare Capital Partners purchased 14,562 shares at $9.22/share ($134K total), increasing its stake to 5M+ shares (46% ownership). This follows Venrock’s 43,707-share purchase on January 30 at ~$9.20/share ($402K).
The buying spree aligns with key developments:
🔹 February 3: Granted 261,000 stock options to 52 new hires to drive growth
🔹 June 17, 2025: FDA decision deadlin...

$Pfizer (PFE.US)$  Phase 3
$Regenxbio (RGNX.US)$  Phase 3
$Annovis Bio (ANVS.US)$  Phase 3
$Atea Pharmaceuticals (AVIR.US)$  Phase 3
$Ironwood Pharmaceuticals (IRWD.US)$  Phase 3
$Alnylam Pharmaceuticals (ALNY.US)$  Phase 3
$Vertex Pharmaceuticals (VRTX.US)$  Phase 3
$KalVista Pharmaceuticals (KALV.US)$  Phase 3
$Axsome Therapeutics (AXSM.US)$  Phase 3
$Novocure (NVCR.US)$  Phase 3
$ROCHE HOLDING AG (RHHBY.US)$  Phase 3
$FibroGen (FGEN.US)$  Phase 3
$Applied Therapeutics (APLT.US)$  Phase 3
$ACADIA Pharmaceuticals (ACAD.US)$  Phase 3...